MetaCap

Nanobiotix S.A. (NBTX) vs Nuvation Bio (NUVB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nanobiotix S.A. (NBTX) has outperformed Nuvation Bio (NUVB) over the past year, gaining 26.6% versus a loss of 45.6%. Over five years, NBTX leads with a +214.0% price change compared with -53.5% for NUVB. Nanobiotix S.A. is the larger company by market cap ($1.35 billion vs $1.34 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NBTX+26.61%NUVB-45.64%
+174%+59%-56%
Nov 21, 20251 yearNov 20, 2026
NBTX+185.87%NUVB-58.01%
+483%+183%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NBTX versus NUVB key metrics
MetricNBTXNUVB
Share price$26.50$3.80
Market cap$1.35B$1.34B
1-day change-2.98%-0.26%
YTD return+14.62%-57.59%
1-year return+26.61%-45.64%
5-year return+213.98%-53.49%
EPS (TTM)$-1.27$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$62.90M
Revenue growth (YoY)—+698.96%
Net income (latest FY)—$-204.63M
Operating margin—-338.72%
Net margin—-325.31%
52-week high$57.14$9.75
52-week low$19.14$3.71
Distance from 52-week high-53.62%-61.03%
Analyst consensusnonestrong_buy
Avg. price target upside+101.06%+227.63%
Average volume148.94K5.24M
Shares outstanding50.95M352.02M
Employees98310
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NBTX has outperformed NUVB by 72.2 percentage points over the past year.

About Nanobiotix S.A.

NBTX stock →

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About Nuvation Bio

NUVB stock →

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees

NBTX vs NUVB FAQ

Which is bigger, Nanobiotix S.A. or Nuvation Bio?

Nanobiotix S.A. (NBTX) is larger, with a market capitalization of $1.35B compared with $1.34B for Nuvation Bio (NUVB).

Which stock has performed better over the past year, NBTX or NUVB?

NBTX returned +26.61% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.

Are Nanobiotix S.A. and Nuvation Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons